🔎 Trials Near Me

Home › NCT07512427

Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants

RecruitingPhase 1/2Healthy volunteers welcome

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of OPK-88006 in Healthy and Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) Participants

Who can join

Ages 18 to 75 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Part A (SAD)

Inclusion Criteria:

* Adults aged 18-65 years.
* BMI ≥27 and ≤35 kg/m².
* Good general health per investigator assessment.
* Willing to comply with contraception, trial procedures, and stable diet/exercise.

Exclusion Criteria:

* Significant uncontrolled medical or psychiatric history.
* History of pancreatitis, cancer (within 5 years), or substance misuse.
* Clinically significant abnormal labs (e.g., liver enzymes, low platelets) or ECG findings.
* Recent use of prohibited medications (GLP-1 agonists, anti-obesity drugs).
* Pregnant, lactating, or planning pregnancy.

Part B (MAD)

Inclusion Criteria:

* Adults aged 18-75 years.
* Presumed MASH (defined by metabolic risk factors and specific liver tests).
* BMI ≥27 and ≤40 kg/m² with stable weight.
* Willing to comply with contraception, trial procedures, and stable diet/exercise.

Exclusion Criteria:

* Significant uncontrolled medical or psychiatric history.
* History of other liver diseases, cirrhosis, or hepatic decompensation.
* History of pancreatitis, cancer (within 5 years), or substance misuse.
* Clinically significant abnormal labs (e.g., elevated liver enzymes, HbA1c ≥9.5%) or ECG findings.
* Recent use of prohibited medications (GLP-1 agonists, anti-obesity drugs).
* Pregnant, lactating, or planning pregnancy.

About the study

Two-part Phase 1/2 study of OPK-88006, including an open-label SAD phase in healthy participants and a double-blind, randomized, placebo-controlled MAD phase in participants with presumed MASH, to evaluate safety, PK, and MASH related pharmacodynamic changes compared to placebo.

What is being tested

Sponsor: OPKO Health, Inc. · Participants: 30 · Started: Jul 24, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07512427

Locations in the U.S.

FloridaOPKO study site, Miami

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.